These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


497 related items for PubMed ID: 1535124

  • 1. Management of chemotherapy-related nausea and vomiting using a serotonin antagonist.
    Egan AP, Taggart JR, Bender CM.
    Oncol Nurs Forum; 1992 Jun; 19(5):791-5. PubMed ID: 1535124
    [Abstract] [Full Text] [Related]

  • 2. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [Abstract] [Full Text] [Related]

  • 3. Nurses' perceptions of antiemetic effectiveness.
    Rhodes VA, McDaniel RW, Simms SG, Johnson M.
    Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
    [Abstract] [Full Text] [Related]

  • 4. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
    Mitchell PL, Evans BD, Allan SG, Forgeson GV, Mak D, Neave L, Humm G, Langley G, Dickson D, Harvey VJ.
    N Z Med J; 1992 Mar 11; 105(929):73-5. PubMed ID: 1532054
    [Abstract] [Full Text] [Related]

  • 5. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA.
    Cancer J Sci Am; 1998 Mar 11; 4(2):72-7. PubMed ID: 9532406
    [Abstract] [Full Text] [Related]

  • 6. Emesis as a complication of cancer chemotherapy: pathophysiology, importance, and treatment.
    Graves T.
    Pharmacotherapy; 1992 Mar 11; 12(4):337-45. PubMed ID: 1387707
    [Abstract] [Full Text] [Related]

  • 7. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS.
    Oncol Nurs Forum; 1997 Aug 11; 24(7 Suppl):33-40. PubMed ID: 9282379
    [Abstract] [Full Text] [Related]

  • 8. Ondansetron: a new entity in emesis control.
    Graves T.
    DICP; 1990 Nov 11; 24(11 Suppl):S51-4. PubMed ID: 2148659
    [Abstract] [Full Text] [Related]

  • 9. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME, Higa GM.
    J Oncol Pharm Pract; 2010 Dec 11; 16(4):233-44. PubMed ID: 20085961
    [Abstract] [Full Text] [Related]

  • 10. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J.
    Expert Opin Drug Saf; 2004 May 11; 3(3):231-48. PubMed ID: 15155151
    [Abstract] [Full Text] [Related]

  • 11. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R, Aapro M, Blower PR.
    Cancer Chemother Pharmacol; 2005 Sep 11; 56(3):231-8. PubMed ID: 15838653
    [Abstract] [Full Text] [Related]

  • 12. Parenteral ondansetron for the treatment of chemotherapy- and radiation-induced nausea and vomiting.
    Burnette PK, Perkins J.
    Pharmacotherapy; 1992 Sep 11; 12(2):120-31. PubMed ID: 1533280
    [Abstract] [Full Text] [Related]

  • 13. Management of nausea and vomiting caused by anticancer drugs: state of the art.
    Pisters KM, Kris MG.
    Oncology (Williston Park); 1992 Feb 11; 6(2 Suppl):99-104. PubMed ID: 1532744
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB.
    Clin Adv Hematol Oncol; 2004 May 11; 2(5):284-9. PubMed ID: 16163194
    [Abstract] [Full Text] [Related]

  • 16. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F.
    J Intraven Nurs; 1993 May 11; 16(2):84-9. PubMed ID: 8478782
    [Abstract] [Full Text] [Related]

  • 17. Ondansetron--the first of a new class of antiemetic agents.
    Chaffee BJ, Tankanow RM.
    Clin Pharm; 1991 Jun 11; 10(6):430-46. PubMed ID: 1829668
    [Abstract] [Full Text] [Related]

  • 18. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M.
    Oncol Nurs Forum; 1997 Aug 11; 24(7 Suppl):20-32. PubMed ID: 9282378
    [Abstract] [Full Text] [Related]

  • 19. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R, Perumal RV, Pandi PV.
    Pharmazie; 2005 Feb 11; 60(2):83-96. PubMed ID: 15739895
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Grunberg SM.
    J Support Oncol; 2004 Feb 11; 2(1 Suppl 1):1-10, inside back cover; quiz 11. PubMed ID: 16117016
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 25.